AR070530A1 - Comprimido de desintegracion oral - Google Patents
Comprimido de desintegracion oralInfo
- Publication number
- AR070530A1 AR070530A1 ARP090100682A ARP090100682A AR070530A1 AR 070530 A1 AR070530 A1 AR 070530A1 AR P090100682 A ARP090100682 A AR P090100682A AR P090100682 A ARP090100682 A AR P090100682A AR 070530 A1 AR070530 A1 AR 070530A1
- Authority
- AR
- Argentina
- Prior art keywords
- disintegrating tablet
- classes
- oral disintegrating
- group
- tablet according
- Prior art date
Links
- 235000012239 silicon dioxide Nutrition 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 abstract 2
- 229960004588 cilostazol Drugs 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000019505 Deglutition disease Diseases 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- -1 flavorings Substances 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000008012 organic excipient Substances 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a un comprimido desintegrante oral que comprende cilostazol, manitol, sacárido distinto de manitol, sustancia inorgánica, y agente desintegrante, así como excipiente orgánico y deslizante, que es posible tomar con manipulacion sencilla por muchos pacientes a los cuales se aplican los comprimidos de cilostazol, especialmente pacientes de edad avanzada y pacientes que sufren de disfagia. Reivindicacion 4: El comprimido desintegrante oral de acuerdo con la reivindicacion 3, caracterizado porque el deslizante es una o más clases de deslizantes seleccionadas del grupo que consiste de dioxido de silicio hidratado, ácido silícico anhidro liviano, y ácido silícico anhidro pesado. Reivindicacion 7: El comprimido desintegrante oral de acuerdo con la reivindicacion 6, caracterizado porque el excipiente orgánico es una o más clases de excipientes seleccionadas del grupo que consiste de almidones y celulosa. Reivindicacion 13: El comprimido desintegrante oral de acuerdo con cualquiera de las reivindicaciones 1 a 12 caracterizado porque opcionalmente también puede comprender una o más clases de aditivos seleccionado del grupo que consiste de lubricantes, edulcorantes, sustancias saborizantes, aromatizantes, aglutinantes y colorantes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008050460 | 2008-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070530A1 true AR070530A1 (es) | 2010-04-14 |
Family
ID=40718911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100682A AR070530A1 (es) | 2008-02-29 | 2009-02-27 | Comprimido de desintegracion oral |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2262487A2 (es) |
| JP (1) | JP2011513194A (es) |
| AR (1) | AR070530A1 (es) |
| CL (1) | CL2009000452A1 (es) |
| PE (1) | PE20091560A1 (es) |
| TW (1) | TW200936184A (es) |
| WO (1) | WO2009107864A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8779146B2 (en) | 2010-04-28 | 2014-07-15 | Nuformix Limited | Cilostazol cocrystals and compositions |
| ES2422657B1 (es) * | 2012-02-10 | 2014-06-11 | Laboratorios Normon S.A. | Composición farmacéutica sólida de cilostazol |
| EP2875830A4 (en) | 2012-07-20 | 2016-02-24 | Otsuka Pharma Co Ltd | TABLET HAVING DRY INK FILM ON THE SURFACE THEREOF, AND INK FOR INKJET PRINTER |
| EP3023109A4 (en) | 2013-07-19 | 2017-01-04 | Sanwa Kagaku Kenkyusho Co., Ltd | Orally disintegrating tablet |
| CN105555316B (zh) * | 2013-09-27 | 2020-07-07 | 株式会社大赛璐 | 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂 |
| US10231914B2 (en) * | 2015-06-02 | 2019-03-19 | Lynette Batton | Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate |
| EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| JP4802436B2 (ja) * | 2000-04-12 | 2011-10-26 | Ｍｓｄ株式会社 | 口腔内崩壊型組成物及び口腔内崩壊型製剤 |
| JP4637338B2 (ja) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | シロスタゾール有核錠 |
| JP4551627B2 (ja) * | 2003-02-28 | 2010-09-29 | 東和薬品株式会社 | 口腔内崩壊錠剤の製造方法 |
| JP3841804B2 (ja) * | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
| WO2005037254A1 (ja) * | 2003-10-15 | 2005-04-28 | Fuji Chemical Industry Co., Ltd. | 口腔内速崩壊性錠剤 |
| TWI383809B (zh) * | 2005-06-29 | 2013-02-01 | Otsuka Pharma Co Ltd | 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末 |
| WO2007029376A1 (ja) * | 2005-09-02 | 2007-03-15 | Fuji Chemical Industry Co., Ltd. | 口腔内速崩壊性錠剤 |
-
2009
- 2009-02-26 EP EP09714454A patent/EP2262487A2/en not_active Withdrawn
- 2009-02-26 WO PCT/JP2009/054115 patent/WO2009107864A2/en not_active Ceased
- 2009-02-26 JP JP2010504975A patent/JP2011513194A/ja active Pending
- 2009-02-27 CL CL2009000452A patent/CL2009000452A1/es unknown
- 2009-02-27 TW TW098106341A patent/TW200936184A/zh unknown
- 2009-02-27 AR ARP090100682A patent/AR070530A1/es unknown
- 2009-02-27 PE PE2009000311A patent/PE20091560A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2262487A2 (en) | 2010-12-22 |
| CL2009000452A1 (es) | 2010-03-26 |
| TW200936184A (en) | 2009-09-01 |
| PE20091560A1 (es) | 2009-10-30 |
| JP2011513194A (ja) | 2011-04-28 |
| WO2009107864A3 (en) | 2009-12-03 |
| WO2009107864A2 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070530A1 (es) | Comprimido de desintegracion oral | |
| AR081776A1 (es) | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion | |
| ECSP088281A (es) | Moduladores del metabolismo y tratamiento de los trastornos metabólicos | |
| UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
| MY157661A (en) | Bendamustine pharmaceutical compositions | |
| PE20142440A1 (es) | Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina | |
| CR20110658A (es) | Antagonistas de la trayectoria hedgehog de ftalazina desustituida | |
| BR112012007412A2 (pt) | tabletes transformáveis de forma oral. | |
| UY32820A (es) | Composiciones dermatologicas de antagonistas del receptor dp2 | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| CL2009000727A1 (es) | Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras. | |
| MY164204A (en) | Formulations comprising polyethylene glycol | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| MX2015012783A (es) | Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13). | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| CU20140114A7 (es) | Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné | |
| CO6300935A2 (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
| DOP2015000089A (es) | Composición de difenidol de liberación prolongada | |
| UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
| MA32461B1 (fr) | Dronedarone pour la prevention de cardioversion | |
| MX2015009348A (es) | Composiciones hemostaticas. | |
| CL2011000614A1 (es) | Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras. | |
| MX2015015537A (es) | Formulacion de pastillas de nicotina. | |
| AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
| PE20091098A1 (es) | Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |